Efficacy and Safety of Oral JAK Inhibitors as Monotherapy in Moderate‐to‐Severe Atopic Dermatitis: A Systematic Review and Meta‐Analysis
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/1187860 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Dermatologic Therapy, online erschienen am 15.07.2026. Verfasst von XinWei Xie und 5 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Janus kinase (JAK) inhibitors, as emerging drugs for the treatment of atopic dermatitis (AD), have demonstrated promising therapeutic potential.
Objectives
To evaluate the efficacy and safety of oral JAK inhibitors as monotherapy in moderate‐to‐severe AD.
Methods
We searched the PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, Global Resource for Eczema Trials (GREAT) databases, CNKI, and Wanfang Database from the establishment of the databases to February 11, 2025. Randomized controlled trials (RCTs) comparing monotherapy of oral JAK inhibitors with placebo/excipient in patients with AD were included. Six outcome measures were analyzed, including the 75% and 90% improvement response rate of the Eczema Area and Severity Index (EASI), percentage change in the EASI score, the Investigator’s Global Assessment (IGA) response, and an improvement of ≥ 4 points in the score on the pruritus Numerical Rating Scale (NRS), as well as safety outcomes. Outcomes We included 9 RCTs (involving a total of 4432 patients). These trials evaluated the efficacy of three different oral JAK inhibitors (abrocitinib, baricitinib, and upadacitinib) in patients with moderate‐to‐severe AD. The results showed that oral JAK inhibitors were more effective than placebo in the above five analyzed outcome measures. In terms of achieving the EASI‐75 and EASI‐90 response, reducing the percentage change in the EASI score, the IGA 0/1 response rate, and an improvement of ≥ 4 points in the pruritus NRS, 30 mg of upadacitinib was more effective than all other doses of JAK inhibitors, and baricitinib had a relatively weaker overall efficacy. The safety analysis revealed that the use of JAK inhibitors, especially upadacitinib, led to a higher incidence of adverse events during treatment (odds ratio [OR]: 1.67, 95% confidence interval [CI]: 1.32–2.12, p < 0.0001), but there was no significant difference for baricitinib ( p > 0.05).
Conclusions
Oral JAK inhibitors are effective in treating AD. 30 mg of upadacitinib is the most effective, but has a relatively high risk of adverse events. Baricitinib is less effective overall, yet shows good safety with the mildest side effects. Longer‐term trials are needed to confirm these findings.
Zitieren
APA
Xie, X., Peng, L., Li, A., Xu, L., Tan, Y., & Liu, C. (2026). Efficacy and Safety of Oral JAK Inhibitors as Monotherapy in Moderate‐to‐Severe Atopic Dermatitis: A Systematic Review and Meta‐Analysis. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/1187860
Vancouver
Xie X, Peng L, Li A, Xu L, Tan Y, Liu C. Efficacy and Safety of Oral JAK Inhibitors as Monotherapy in Moderate‐to‐Severe Atopic Dermatitis: A Systematic Review and Meta‐Analysis. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/1187860
BibTeX
@article{Xie2026,
author = {Xie, XinWei and Peng, LiLi and Li, AoQi and Xu, LiQiong and Tan, Yu and Liu, ChaoSheng},
title = {Efficacy and Safety of Oral JAK Inhibitors as Monotherapy in Moderate‐to‐Severe Atopic Dermatitis: A Systematic Review and Meta‐Analysis},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/1187860}
}
EUVIMED